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Introduction
Gene therapy offers the prospect of selectively introducing genes into cancer cells, rendering them susceptible to specific antitumor drugs. A number of investigators have shown dramatic tumor sensitization to the purine nucleoside analog, ganciclovir (GCV), after transduction with the herpes simplex virus type 1 (HSV-1) thymidine kinase gene. [1] [2] [3] Unlike the cellular thymidine kinase, HSV-1 thymidine kinase (TK) is able to phosphorylate GCV and acyclovir (ACV) to their monophosphorylated states. Cellular kinases further phosphorylate the nucleotide to its triphosphorylate which, when incorporated into nascent DNA, inhibits and terminates further chain elongation by DNA polymerase and leads to cell death. [4] [5] [6] Previous investigators utilizing mouse models have shown that while only a small percentage of the tumor is transduced with retroviral vectors, the tumors completely regress in the presence of GCV. 2 This phenomenon, know as the bystander effect, has been partially attributed to the transfer of phosphorylated prodrugs to neighboring (non-TK-expressing) cells via gap junctions. [7] [8] [9] Gap junc-tions are channels formed by proteins from the connexin family, eg connexin-43, the level of which has been shown to determine the amount of intracellular communication between cells. 10 An additional component of the bystander effect has been attributed to an immunemediated effect due to the introduction of foreign proteins, especially expression of HSV-1 TK. 11 Currently, only GCV is used as a prodrug with HSV-1 thymidine kinase in clinical trials although the immunosuppressive side-effects of dosages required for tumor regression limit its efficacy. ACV is relatively nontoxic at high doses but the very high K m HSV-1 TK displays for ACV precludes its use in suicide gene therapy applications. Novel HSV-1 TKs with increased specificity for phosphorylating GCV and/or ACV could enhance tumor cell killing and reduce prodrug-mediated toxicity to normal cells by decreasing the effective dosage of GCV or by allowing the use of ACV in place of GCV.
A previous report described the creation of drugspecific TKs using random sequence mutagenesis in which over a million HSV-1 TK mutants were screened for increased specificity towards GCV and ACV. 12 Of the 426 clones that displayed TK activity toward thymidine, eight mutants demonstrated heightened GCV and/or ACV sensitivity when expressed in mammalian cells (Ref. 12 
and data not shown). Two mutants expressed in BHK tk
− cells conferred superior sensitivity to GCV 12 HSV-1 thymidine kinase mutant MS Kokoris et al 1416 while the remaining six mutants conferred enhanced sensitivity only to ACV (data not shown). One of these, mutant 75, conferred sensitivity to the thymidine kinasedeficient cell line by both GCV and ACV 10 and will be reported elsewhere. Here we report the sensitivity to GCV and ACV conferred to a rat glioma cell line in vitro, in vivo in a xenograft mouse model, and kinetic characterization and molecular modeling of a mutant thymidine kinase that contains six amino acid substitutions. 12 The results reported here suggest that this mutant thymidine kinase offers a significant advantage for suicide gene therapy to that of the widely used wild-type HSV-1 thymidine kinase gene.
Results
In vitro prodrug sensitivity assays Previously we had reported decreased IC 50 values in response to GCV or ACV treatment of BHK tk − cells transfected with mutant 30 12 compared with those transfected with wild-type TK. In order to analyze the efficiency of TK mutants we have extended these studies to utilize rat C6 glioma cells. Rat C6 glioma cells have served as a model system to evaluate the efficacy of the TK/GCV paradigm in brain and subcutaneously. 2, 10, [13] [14] [15] A new expression vector, pREP8⌬7:TK-GFP, was constructed to provide expression of green fluorescent protein (GFP) for detection purposes and thymidine kinase (wild-type or mutant 30; pREP8⌬7:30-GFP) (Figure 1 ). These vectors were used to transfect stably rat C6 glioma cells that were subsequently selected for histidinol resistance and sorted for GFP expression as described in Materials and methods. Pools of C6 transfectants were transferred to 96-well microtiter plates as described in the Materials and methods section. Dose ranges of GCV or ACV were applied (n = 8 for each group). Cell survival was ascertained using alamar Blue (Biosource, Hopkin- Figure 2 . This experiment was performed several times using different pools of transfectants with similar results. Microscopically, no cells were visible in the highest concentration of prodrugs with mutant 30 despite the artifactual reading of 20% survival. This is likely due to dye activated by remaining cell membrane debris.
In the presence of GCV, wild-type TK-expressing C6 cells display an IC 50 of 30 m whereas mutant 30 displays an IC 50 value of 0.025 m. In a similar experiment in which ACV was used, wild-type TK-expressing C6 cells were not killed at doses up to 100 m. Mutant 30, however, displays an IC 50 of 0.7 m with ACV. The increase in sensitivity that mutant 30 confers to cells in the presence of either prodrug is on the order of three to four logs. This brings the effective dose of each prodrug into the nanomolar range. When pools of transfected cells were analyzed by ELISA, the level of TK protein in mutant 30-expressing cells was 2.7-fold higher than that in wild-type TK-expressing cells. Because the level of TK protein can influence the amount of prodrug-mediated cell killing (data not shown), it is possible that some, but not all, of the difference in IC 50 values is due to the larger amount of mutant 30 protein.
Xenograft tumor model
As described in detail in the Materials and methods section, pools of rat C6 glioma cells transfected with pREP8⌬7:dual-GFP, pREP8⌬7:TK-GFP or pREP8⌬7:30-GFP were injected subcutaneously into nude mice (n = 5). After 5 days, mice were treated with saline, GCV (0.5 or 5 mg/kg) or ACV (5 or 25 mg/kg) intraperitoneally, twice a day for 5 days. During the saline or prodrug administration period and for an additional 6 days, tumor diameter was monitored by caliper measurements every other day. Figure 3 displays the time-course of tumor growth over this period.
At the start of prodrug treatment all the tumors were between 2 and 3 mm in diameter. In both prodrugtreated and saline-treated non-TK-expressing groups (pREP8⌬7:dual-GFP) the tumors grew unchecked (Table 1 and Figure 3 ). The mean tumor size for the vector-transfected tumor cells was 10.2 mm. Wild-type TK and mutant 30 transfectant tumor mean sizes were 7.9 mm and 9.15 mm, respectively. From analyses using the Fisher protected LSD test, there was only a marginally significant difference (P = 0.055) in size of the saline-treated wild-type TK-expressing and mutant 30-expressing tumors at the end of the experiment.
Tumor cells transfected with the vector only showed no statistically significant difference in tumor size between mice treated with saline or prodrug ( Table 1 and Figure 3 ). GCV-treated mice had a mean tumor size of 10.1 mm (GCV 5 mg/kg) and 9.2 mm (GCV 0.5 mg/kg) with a P value of 0.2915 (ANOVA). Mice treated with ACV also displayed only a marginal difference in tumor sizes (P = 0.0891) with mean tumor sizes of 8.6 mm (ACV at 25 mg/kg), 10.25 mm (ACV at 5 mg/kg) and 10.2 mm for saline-treated mice. The reduced vector-transfected tumor size with ACV 25 mg/kg was unexpected and may reflect the general inhibition of proliferation that was observed in vitro with the C6 cell lines at high ACV concentrations.
Comparison of GCV-treated versus saline-treated wildtype TK-expressing tumors indicates that there is no difference between the low GCV dose (GCV 0.5 mg/kg) and saline treatment (P = 0.2096) ( Table 1 ). However, the high dose of GCV (5 mg/kg) was able to limit tumor growth partially in the wild-type TK-expressing tumors (P = 0.0002). Mean tumor sizes were 4.85 mm, 7.15 mm and 7.9 mm for mice treated with GCV at 5 mg/kg, 0.5 mg/kg or saline, respectively. Mice bearing wild-type TK-expressing tumors showed little, if any, significant differences in tumor size after ACV treatment. ACV at 5 mg/kg provided no reduction in tumor size compared with the saline-treated mice (7.15 mm versus 7.9 mm, P = 0.2096). Mice treated with ACV at 25 mg/kg displayed only a slight, albeit significant, difference in mean tumor size of 6.19 mm (P = 0.0237), similar to what was seen with vector-transfected tumors at the same ACV dose. There was no difference in mean tumor sizes in the ACV 25 mg/kg group when wild-type TK-expressing and vector-transfected tumors were compared (P = 0.351).
In contrast to tumors expressing wild-type TK where only the highest GCV dose substantially limited tumor growth, all prodrug treatments of mice bearing mutant 30-expressing tumors elicited a strong response (Table 1 and Figure 3 ). Perhaps most striking was the absence of visible tumors in three of the five mice bearing mutant 30-expressing tumors that had been treated with GCV at 5 mg/kg (mean tumor size of 0.45 mm versus saline tumor mean of 9.15 mm, P = 0.0001). Even at 0.5 mg/kg GCV, the mutant 30 tumors were also dramatically reduced compared with the saline control group (2.5 mm versus 9.15 mm, P = 0.0001) as well as in comparison with the mice treated with GCV at 5 mg/kg (P = 0.0004). Treatment of mice bearing mutant 30-expressing tumors was also effective at both ACV doses compared with the respective saline control. The mean tumor size was 9.15 mm for the saline group, 6.95 mm for the ACV at 5 mg/kg group (P = 0.0124 saline versus ACV 5 mg/kg) and 6.1 mm for the ACV at 25 mg/kg treatment group (P = 0.0015, saline versus ACV 25 mg/kg). While the wildtype TK-expressing tumors did not differ in size from the vector control tumors at ACV 25 mg/kg (P = 0.351), there was significant difference in mean tumor size when mutant 30-expressing tumors were compared with vector-transfected tumors (P = 0.0045).
To evaluate the effect of the different prodrugs on tumors expressing either wild-type TK or mutant 30, the mean tumor size of the prodrug-treated group was divided by the mean tumor size of the saline control group for each TK set ( Table 2 ). A value of 1 indicates the same tumor size as the saline-treated group. At both GCV concentrations, there were large differences in tumor size between wild-type TK-expressing tumors and mutant 30-expressing tumors. At GCV 0.5 mg/kg, the calculated values were 0.614 for wild-type TK and 0.049 for mutant 30 (P = 0.0001). At GCV 5 mg/kg, the calculated values were 0.905 for wild-type TK and 0.273 for mutant 30 (P = 0.0001). Clearly tumors expressing mutant 30 were much more sensitive to GCV than those expressing wildtype TK. Indeed, even a 10-fold lower dose of GCV (0.5 mg/kg) was significantly more effective at limiting tumor growth with mutant 30-expressing tumors than those expressing wild-type TK and treated with GCV at 5 mg/kg (P = 0.0001).
Wild-type TK-expressing tumor size was not effected by ACV at 5 mg/kg whereas mutant 30-expressing tumors were significantly smaller (P = 0.0003) ( Table 2 ). In a side by side comparison, there appears to be no difference between wild-type TK and mutant 30-expressing tumor sizes after treatment with the higher ACV level (25 mg/kg) (P = 0.0723). However, there was a marginal difference in the sizes of tumors transfected with the vector alone with ACV 25 mg/kg compared with the saline control (8.6 mm versus 10.2 mm, respectively). When wild-type TK-expressing tumors were compared with tumor cells containing vector DNA (ACV/saline), no significant difference was observed (P = 0.351). In contrast, there was a statistically significant difference between mutant 30 tumor sizes and vector alone tumors (P = 0.0046). This suggests that tumors expressing mutant 30 do respond to ACV at both high and low doses whereas tumors expressing wild-type TK do not. The lack of a significant difference in mutant 30-expressing tumors treated with ACV 5 mg/kg or ACV 25 mg/kg is perhaps indicative of the poor solubility and therefore poor bioavailability of ACV at the higher dose.
Figure 3 Growth of tumors expressing TK during and after (a) GCV or (b) ACV treatment. Pools of rat C6 cells transfected with vector (pREP8⌬7:dual-GFP), TK (pREP8⌬7:TK-GFP) or mutant 30 (pREP8⌬7:30-GFP) were used to seed tumors in nude mice. After 5 days (days 0-4) to allow for visible tumor formation, saline, GCV (0.5 mg/kg or 5 mg/kg) or ACV (5 mg/kg or 25 mg/kg) were administered twice a day for 5 days (days 5-9). During this period (days 5-9) and for an additional 6 days (days 10-15), tumor diameter was measured every other day (n = 5 for each group).

Bystander experiments
Cells that neighbor TK-expressing cells but do not contain TK die when treated with GCV. This phenomenon, know as the 'bystander effect', has been attributed to metabolic cooperation through gap junctions, an immune component or to the uptake of apoptotic vesicles from cell expressing TK. [7] [8] [9] [10] [11] To evaluate further the improved tumor cell sensitization to prodrugs by mutant 30, tumors were established using mixtures of non-TK-expressing C6 transfectants (vector transfectants) and either wild-type TK or mutant 30-expressing transfectants at ratios of 80:20 and 95:5 (vector:TK or mutant 30). Tumor growth in the presence of GCV (5 mg/kg), ACV (25 mg/kg) or saline was monitored as described in Materials and methods.
Tumors containing an 80:20 or 95:5 vector to wild-type TK cell ratio were not affected by either GCV or ACV when compared with the saline-treated group for the respective cell mixture ( Figure 4 and Table 3 ). Whereas the wild-type TK-expressing tumors showed no bystander effect under any condition, the mutant 30-expressing tumors (80:20, vector:mutant 30) demonstrated a significant impairment in tumor growth in mice treated with GCV (P = 0.0001) compared with the saline control. No difference in tumor growth from the saline control was observed in the other treatment or vector:mutant 30 cell ratio groups.
Purification of wild-type and mutant enzymes
In an attempt to understand the biochemical nature of how the amino acid substitutions in mutant 30 (six amino acid changes, Figure 5 ) 12 affect substrate binding and utilization, the mutant and wild-type TKs were purified by affinity chromatography. A one-step affinity purification 16 of the wild-type and mutant TK yielded proteins that were near homogeneity as estimated from Coomassie-stained SDS containing polyacrylamide gels (data not shown).
Substrate binding
For the kinetic studies, both enzymes (wild-type and mutant 30) displayed Michaelis-Menten kinetics throughout the concentration ranges used for each substrate and no substrate inhibition or activation was observed. The K m values were determined from Lineweaver Burk plots (data not shown) and are shown in Table 4 . The Michaelis constants (K m ) of wild-type HSV-1 TK for the substrates thymidine, GCV and ACV of 0.38 m, 47.6 m and 417 m, respectively, are in close agreement with previously reported values. [17] [18] [19] The K m values for mutant 30 were higher than wildtype for GCV and thymidine substrates (Table 4 ) and the same as wild-type TK when ACV was the nucleoside substrate. The most remarkable difference was the 35-fold higher K m with thymidine as the substrate (13.3 m) for mutant 30, compared with the wild-type K m (0.38 m). The turnover numbers (k cat ) for mutant 30 were substantially reduced from that of the wild-type on all substrates tested; thymidine (86-fold less), ACV (eight-fold less) and GCV (six-fold less). The specificity constant, which reflects both k cat and K m (k cat /K m ), is multiple orders of magnitude lower (3000-fold) for mutant 30 than the wildtype for thymidine but is only nine-fold and 40-fold lower for ACV and GCV, respectively.
From a comparison of the specificity constants between wild-type and mutant 30 enzymes for GCV and ACV, one might not predict that mutant 30 would elicit hugely enhanced prodrug sensitivity to cells. However, because endogenous thymidine within the cell competes with the prodrug for the active site, it is important to consider the ratio of specificity constants for prodrug and thymidine. We used the equation [k cat /K m (prodrug)]/[k cat /K m (thymidine) + k cat /K m (prodrug)] to take this into account (Table 4) . With GCV as the prodrug, mutant 30 displays a 67-fold higher value than the wild-type enzyme does. With ACV as the prodrug, mutant 30 displays a 344-fold higher value than the wild-type enzyme does. Clearly mutant 30 displays an enormous advantage over the wild-type enzyme for both prodrugs when competition for the active site is considered. 0.119
The k cat values were calculated using the equation V max = k cat [E] where E = total enzyme concentration and is based on one active site/monomer. Assay conditions are described in Materials and methods.
Molecular modeling
As described in Materials and methods the six amino acid substitutions found in mutant 30 were integrated into the structure of HSV-1 TK 20 with thymidine or GCV bound. Figure 6 is a global picture of HSV-1 TK showing the location of each of the six alterations. Four of the substitutions lie outside the active site, either within a turn (A152V) or on a beta strand (L159I, I160L, F161A). One additional residue outside the active site juts into the dimer interface (L169F). One residue, A168Y, appears to directly impact the active site by interfering with substrate binding and is displayed in Figure 7 .
In the thymidine bound structure (Figure 7a ), the tyrosine 168 substitution appears to cause residues that are catalytically important to move from their optimal position. For example, R163 and E83 (not shown) hydrogen bond to O5 of thymidine in the native structure, but in the modeled structure thymidine and R163/E83 are pushed apart by the inserted tyrosine, so that this oxygen atom is no longer able to hydrogen bond to either R163 or E83. Q125 forms weak hydrogen bonds with N3 and O4 of the thymine; this interaction is also weakened in the mutant model. Similarly, in the ganciclovir bound structure (Figure 7b ), O4 (the structural equivalent of O5 in thymidine) also seems to be moved to a weaker hydrogen bonding interaction with R163, but not as far as the thymidine. One of the two hydrogen bonds to Q125 is maintained. The stacking interaction with Y172 becomes slightly less optimal and a stabilizing interaction with H58 is also removed. One of the bigger changes in both structures is that Y132 must move aside to accommodate Y168; in fact, Y132 moves toward the cavity made by the F161A mutation, although not into it.
Interestingly, when the mutant thymidine bound structure was modeled without thymidine, Y168 moved into the space occupied by the thymidine. However, since this 38, 39 was modeled in the absence of solvent it only indicates that the side chain could fit in that region, not that it does.
Discussion
The HSV-1 thymidine kinase gene is currently used in over 30 clinical trials for gene therapy of a variety of human cancers. In cells expressing HSV-1 TK, ganciclovir is phosphorylated and eventually leads to cell death as a result of interfering with the ability to replicate DNA. Because the high dose of GCV required to achieve complete tumor regression is immunosuppressive, we sought to re-engineer HSV-1 TK to phosphorylate GCV more efficiently. Furthermore, we sought to create an enzyme capable of activating the relatively nontoxic prodrug ACV for effective cell killing in a gene therapeutic setting. Previously, we had reported the generation of over a million variants of HSV-1 TK using random sequence mutagenesis in combination with functional selection in E. coli. Of the 10 mutant TKs identified, eight were subsequently shown to impart lower IC 50 values to stably transfected cells when treated with GCV or ACV than those transfected with the wild-type TK construct (data not shown). One of these eight, mutant 30, has been examined in in vitro tumor cell sensitivity studies, in an in vivo xenograft tumor model, by kinetic characterization and by molecular modeling, the results of which are reported here.
We previously demonstrated that BHK tk − cells stably transfected with mutant 30 showed enhanced sensitivity to GCV. 12 To extend these studies to a relevant tumor cell line we stably transfected the widely used rat C6 glioma cell line to compare the efficacy of wild-type TK-and mutant 30-mediated prodrug cell killing both in vitro and in a xenograft mouse model. Results of prodrug sensitivity assays on pools of rat C6 glioma cells expressing mutant 30 demonstrates a two to three log higher sensitivity to ACV and GCV than pools of wild-type TK transfectants ( Figure 2 ). Because the wild-type TK-expressing cells lack sensitivity to ACV such that an IC 50 value could not be determined, the IC 50 value for mutant 30 with ACV is an under-estimation at 143-fold lower. In cells expressing TK protein and sorted for GFP, TK expression was slightly higher (2.7-fold) in cells transfected with mutant 30 compared with those transfected with the wild-type TK. However, the large magnitude of enhanced cell sensitivity to the prodrugs with mutant 30 (relative IC 50 values of 1200 for GCV and Ͼ143 for ACV) is most likely to be a dominant feature imparted by structural changes caused by the six amino acid substitutions and not simply a reflection of the slightly elevated protein expression level.
A xenograft tumor model was developed using pools of transfected cells that were subcutaneously injected into nude mice. After 5 days to allow visible tumor formation, the mice were treated intraperitoneally with saline, GCV or ACV twice a day for 5 days. Tumor growth over the 5 day treatment period and for an additional 9 days was monitored every other day by caliper measurements of the tumor diameter (Figure 3 ). In the presence of GCV at 0.5 mg/kg, mice bearing wild-type TK tumors displayed no difference in tumor growth compared with the corresponding saline treatment group. This is in stark contrast to the group of mutant 30-expressing tumors that showed a dramatic cessation of tumor growth upon treatment with the same dose of GCV. A noticeable reduction in tumor size was observed between the saline control and GCV at 5 mg/kg treatment groups of mice bearing wildtype TK-expressing tumors, 7.9 mm and 4.85 mm, respectively. In the same comparison with the mutant 30 tumor-bearing mice (saline to GCV at 5 mg/kg), the difference in tumor size is impressive, 9.15 mm versus 0.45 mm, respectively. Not only is tumor growth restricted in cells expressing mutant 30 at a dose that wild-type TK-expressing cells respond marginally to but three of the five mice injected with mutant 30-expressing cells showed no visible tumor at the end of the experiment. Clearly, mutant 30 is able to provide tumor ablation at a dose which only marginally slows tumors expressing wild-type TK. Given the short duration of the prodrug treatment (5 days) compared with that in other reports (14 to 21 days) [9] [10] [11] 13, 14, [21] [22] [23] these results are very compelling.
The low dose of ACV (5 mg/kg) used slowed tumor growth in mice bearing mutant 30 tumors but not in those bearing wild-type TK. At 25 mg/kg ACV both wild-type TK and mutant 30-bearing tumors showed reductions in tumor growth. Because the difference in tumor size between the ACV treatment groups bearing mutant 30 tumors is not significant (P = 0.2785, Table 2 ) and the solubility problem observed with ACV at the higher dose before injection, the bioavailability of ACV may be impacted. The use of valaciclovir, an ester form of ACV, in similar experiments may prove a more effective prodrug than ACV. While the ACV results are less dramatic than those observed with GCV, they still demonstrate that ACV (or valaciclovir) may be a functional alternative that is less toxic and less immunosuppressive than GCV.
The efficacy of HSV-1 TK and GCV as suicide gene and prodrug for the gene therapy of cancer has been widely attributed to the bystander effect. This phenomenon is credited with providing complete tumor regression when only a small percentage of tumor cells are transduced with HSV-1 TK-expressing viral vectors. We were interested in ascertaining whether the increased cell killing we observed with mutant 30 in vitro would enhance the bystander effect in vivo. Towards that end, vector-transfected cells were mixed at a ratio of 80:20 or 95:5 with cells expressing either wild-type TK or mutant 30 and used to seed tumors in nude mice. Mice bearing the 95:5 ratio vector to TK (or mutant 30)-transfected tumor cells did not respond significantly to either GCV or ACV ( Figure 4 and Table 3 ). Furthermore, none of the mice bearing 20% wild-type TK-expressing tumors (80:20 ratio), showed any difference in tumor size compared with the corresponding saline treatment group or in the group of vector:mutant 30 mice treated with ACV. However, there was a significant difference in tumor size in mice bearing tumors containing 20% mutant 30-expressing cells after treatment with GCV. While no bystander effect was observed with wild-type TK under the conditions used, a clear bystander effect was demonstrated with GCV when only 20% of the tumor cells express mutant 30. Such a bystander effect in C6 cells is indeed impressive given that they have been shown to express connexin-43 poorly and to exhibit a low level of intracellular communication via gap junctions by morphological and functional studies. [24] [25] [26] Furthermore, the use of immunocompromised (nude) mice in this study is likely also to preclude the full extent of the bystander effect due to the deficiency of the immune-mediated component.
To examine the impact of the six amino acid substitutions found in mutant 30 on substrate binding and phosphorylation, wild-type and mutant 30 enzymes were purified to near homogeneity and their kinetic parameters determined (Table 4) . Compared with the wildtype TK K m values, mutant 30 displays much poorer K m s for thymidine and GCV with little difference in the K m for ACV. Despite this, in cell culture prodrug sensitivity assays, cells expressing mutant 30 demonstrated a greater degree of sensitivity to both prodrugs than cells transfected with the wild-type TK gene (Figure 2) . One possible explanation for mutant 30's ability to outperform or equal the wild-type enzyme in cell culture experiments is its poor ability to bind thymidine such that even a high K m for a prodrug still provides a kinetic advantage. This can be better viewed by looking at the ratio of prodrug K m to thymidine K m . The GCV/thymidine K m ratio is 125 for wild-type TK whereas that of mutant 30 is much lower at 25 (Table 4) . Likewise the ACV/thymidine K m ratio for wild-type TK is 1097 and 34 for mutant 30. However, if one takes the specificity constants into consideration the k cat /K m (prodrug)/k cat /K m (thymidine) + k cat /K m (prodrug) one sees that mutant 30 has an enormous increase in specificity for both prodrugs. Furthermore, because dTTP has been suggested to bind at or overlap the thymidine binding site, an increased K m for thymidine is likely to alter the ability of dTTP to regulate enzyme activity of mutant 30. 27 These factors indicate that the mutant has a distinct advantage over the wildtype enzyme to catalyze the phosphorylation of GCV or ACV in a milieu consisting of other nucleosides and, in particular, thymidine.
Other means to increase the phosphorylation of GCV have included overexpression of TK and modulations in the nucleotide pool levels to favor GCV phosphorylation. Unfortunately, high levels of HSV-1 TK expressed from a strong promoter such as CMV has been shown to be cytotoxic to certain cells (Ref. 28 and data not shown).
Recently, Aghi et al
29 demonstrated an apparent synergistic enhancement of GCV phosphorylation by HSV-1 TK when it is co-expressed with cytosine deaminase in the presence of 5Ј-fluorocytosine (5FC). Cytosine deaminase converts 5FC to 5Ј-fluorouracil, which is subsequently metabolized to 5Ј-FdUMP, an inhibitor of the de novo pyrimidine metabolizing enzyme, thymidylate synthase. Blockage of this pathway inhibits dTMP production and results in a deficiency of dTPP that ultimately leads to cell death because DNA replication is impeded. When thymidylate synthase is incapacitated, dTMP is primarily supplied by the endogenous thymidine kinase through the salvage of thymidine. Such a reduction in the intracellular concentration of thymidine directly impacts the functionality of the introduced HSV-1 thymidine kinase. Removal of thymidine from the intracellular milieu decreases competition for the TK active site between thymidine and ganciclovir thereby making the substrate binding site more accessible to GCV. Wild-type HSV-1 thymidine kinase has a K m of 0.38 m for thymidine (Table 4) and is sensitive to endogenous levels of thymidine that can range from 1 to 20 m. 30 The high K m that mutant 30 displays towards thymidine (13.3 m, Table 4) suggests that mutant 30 exerts enhanced tumor ablation by altering the ability of thymidine to bind rather than by changing the thymidine pool size. Considering this, a mutant thymidine kinase with a high K m for thymidine and a low K m for GCV or ACV would be ideal for suicide gene therapy. One such mutant has been generated with a K m of 2.64 m for thymidine and 3.33 m for GCV and demonstrates superior tumoricidal effects (manuscript in preparation).
Sequence analysis of mutant 30 indicates that it contains six amino acid substitutions near two highly conserved domains (Sites 3 and 4) 31 ( Figure 5 ). While the mutagenesis and selection studies were carried out before the solution of the crystal structure, the involvement of the region targeted for mutagenesis in binding substrate (thymidine and GCV) is supported by the determined structure. 20 We have used molecular modeling to help visualize the amino acid substitutions found in mutant 30 ( Figures 6 and 7) . Four of the six substitutions appear not to play a major role in substrate binding or structure stability. One change, A152V, lies within a large unstructured turn and is unlikely to confer any functional or structural alteration. The three substitutions spanning the L I F motif (residues 159-161) are found on a beta strand which, because of the overall maintenance in hydrophobicity and slightly smaller size (I L A, respectively), will probably not contribute significantly to the observed alteration in activity. However, the F161A mutation leaves a cavity adjacent to Y132 which may facilitate accommodation of the adjacent A168Y.
Two of the six substitutions, A168Y and L169F, appear to play important roles in enzyme function and possibly stability of mutant 30. Phenylalanine (L169F) juts into the space formed between the monomers and may act to increase stability of the homodimeric protein. The major alterations in K m and k cat for all three substrates observed with mutant 30 are most likely due to the tyrosine at position 168 (A168Y) that appears to protrude into the active site and sterically interfere with binding and catalysis. Interestingly, this particular substitution (A168Y) was found in two additional high activity mutants isolated from this random library. 
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Materials and methods
Materials
Radioisotopes for kinetic assays: [methyl-3 H] thymidine (specific activity, 85 Ci/mmol) was purchased from Amersham (Arlington Heights, IL, USA) and [8- 3 H]-acyclovir (specific activity, 16.9 Ci/mmol) and [8- 3 H]-ganciclovir (specific activity, 17.6 Ci/mmol) were purchased from Moravek Biochemicals (Brea, CA, USA). All other chemicals used for the kinetic assays were purchased from Sigma (St Louis, MO, USA).
In vitro expression vectors The 1.1 kb NcoI/BamHI fragment from pET23d:HSVTK or pET23d:30 12 was subcloned into the NcoI/BamHI sites in the multiple cloning region of pREP8⌬7:dual-GFP. The vector used, pREP8⌬7:dual-GFP, is derived from the mammalian expression vector, pREP8 (Invitrogen, Carlsbad, CA, USA). This vector was modified to remove EBNA and oriP sequences by restriction with BstEII and XbaI and ligation of the blunt-ended vector. The resulting 7 kb vector was designated pREP8⌬7. To allow for expression of a second gene a modified constitutive metallothionein promoter (cMT) was linked to the human growth hormone (hgh) poly A signal by construction of a new polylinker. The cMT-hgh cassette (EcoRI bluntended fragment) was inserted into the SwaI site in pREP8⌬7 such that the pREP8 RSV LTR and cMT promoters are in opposite orientation to one another (bidirectional) (pREP8⌬7:dual). This vector was further modified to provide expression of green fluorescent protein (GFP). GFP (EGFP-1 from Clontech, Palo Alto, CA, USA) was initially subcloned as an NcoI/XbaI fragment into a modified pBluescript SK cloning vector (Stratagene, La Jolla, CA, USA) in which the PstI site was replaced by an NcoI restriction site. From this vector the 753 bp EcoRV/XbaI fragment containing GFP sequences was subcloned into the PacI (blunt-ended)/XbaI restricted pREP8⌬7:dual vector behind the cMT promoter. The resulting vector was sequenced to confirm orientation and junction sites and was designated pREP8⌬7:dual-GFP. To construct the TK-GFP dual expression vectors the 1.1 kb NcoI/BamHI restriction fragments from pET23d containing the wild-type or mutant 30 mutant TK were subcloned individually into the NcoI/BamHI sites in the multiple cloning site region of pREP8⌬7:dual-GFP. All vectors were sequenced to confirm junctions and TK sequences. The new vectors were designated pREP8⌬7:TK-GFP and pREP8⌬7:30-GFP (Figure 1 ).
Rat C6 glioma cell transfections
Ten micrograms of each DNA construct were used to transfect 1 × 10 6 rat C6 glioma cells (ATCC CCL-107) by electroporation. Cells were grown at 37°C in Dulbecco's modified Eagle's medium plus supplements (5% fetal bovine serum, 1 mm sodium pyruvate, 10 mm Hepes, 100 m nonessential amino acids, 100 U/ml penicillin G, 10 g/ml streptomycin sulfate, 292 g/ml l-glutamine, 100 m sodium citrate and 0.0014% NaCl). After 2 days of incubation, the medium was replaced with DMEM minus histidine plus supplements containing 0.125 mm histidinol. After several weeks histidinol-resistant clones (60-120) were collected and pooled. Approximately 200 000 pooled transfectants were bulk sorted using a MoFlo cell sorter (Cytomation, Fort Collins, CO, USA) based on photoactivation and emission of GFP. Data were analyzed using Cyclops software (Cytomation).
ELISA
GammaBind Plus Sepharose (Pharmacia, Uppsala, Sweden) was used to purify the IgG fraction from rabbit polyclonal antiserum derived against HSV-1 thymidine kinase. Six milliliters of unpurified antiserum were subjected to dialysis and column chromatography according to the manufacturer's protocol. Anti-TK IgG was diluted to 0.625 ng/l in phosphate-buffered saline containing 0.05% sodium azide (PBSN) and added to a flat-bottom 96-well high protein binding plate (Dynatech Labs, Chantilly, VA, USA). After an overnight incubation at room temperature, the plate was rinsed twice with 300 l per well 50 m Tris, pH 7.5/200 m NaCl/0.05% Triton X-100/0.05% sodium azide (TTBSN). The residual binding capacity of the plate was blocked by the addition of 100 l per well blocking buffer (TTBSN containing 3% gelatin) and incubation at 37°C for at least 2 h. The wells were washed with 100 l per well TTBSN/1% gelatin for 5 min at 37°C.
For the generation of a standard curve, a serial dilution of purified HSV-1 TK was performed in TTBSN/1% gelatin. To each well 50 l of each dilution was added. In addition to the standard curve, transfected cell lysates were diluted in a small volume of PBSN and added to wells containing the appropriate volume of TTBS/1% gelatin. The plate was then incubated at 37°C for 2 h. The plate was washed twice with 300 l per well TTBSN. A final incubation with TTBSN/1% gelatin was done for 5 min at 37°C.
To each well 50 l biotin-labeled anti-TK IgG (1 ng/l in TTBSN/1% gelatin) was added and left at 37°C for 2 h. Purified anti-TK IgG was conjugated with biotin using a Biotin Protein Labeling Kit (Boehringer Mannheim, Indianapolis, IN, USA). After washing as in the previous step, 50 l per well of streptavidin-alkaline phosphatase conjugate (Vector Laboratories, Burlingame, CA, USA) diluted to 1 ng/l in TTBSN/1% gelatin was added. For detection, 95 l per well p-nitrophenyl phosphate solution was added to each well. To generate the standard curve, the change in A 405 was monitored and plotted. Concentrations of HSV-1 TK found in cell lysates were determined by comparison of A 405 values against the standard curve.
Prodrug sensitivity assays
To determine the cytotoxic effect of GCV and ACV, cells were plated in 96-well microtiter plates at an initial density of 600 cells per well in DMEM plus supplements. After the cells adhered to the plates overnight, ACV or GCV was added in sets of eight wells for each concentration tested. The GCV and ACV concentrations ranged from 0.001 to 0.39 or 1.56 m, respectively, for mutant 30. For the wild-type and vector controls the prodrug concentration ranged from 0.2 to 100 m for GCV and 0.05 m to 25 m for ACV. The plates were incubated for 5 days at which time the redox indicator dye alamar Blue (Biosource, Hopkinton, MA, USA) was added. Cell survival was determined several hours later according to the manufacturer's instruction.
Xenograft tumor model
Pools of C6 cells transfected with pREP8⌬7:dual-GFP (vector), pREP8⌬7:TK-GFP or pREP8⌬7:30-GFP (5 × 10 6 cells in 100 l sodium bicarbonate-buffered saline (pH 7.0)) were injected subcutaneously into 4-to 5-week-old female nude mice (Bkl:BALB/c/nu/nu; B and K Universal, Kirkland, WA, USA) (day 0). Five days after injection (day 5), saline or prodrug treatment was administered by intraperitoneal injection (200 l) twice a day for 5 consecutive days. For GCV, the doses were 0.5 and 5 mg/kg and for ACV the doses were set at 5 and 25 mg/kg. Also starting at day 5, tumor volume was measured by caliper every other day until day 15 at which time the mice were killed. Nude mice were also injected with 80:20 or 95:5 mixtures of vector to TK or vector to mutant 30 transfectant pools to evaluate the degree of bystander effect. Saline, 5 mg/kg GCV or 25 mg/kg ACV were administered as above.
Protein overexpression and purification
Expression of the wild-type and mutant HSV-1 thymidine kinases (pET23d constructs described in Ref. 12 ) was
